Teva intros authorized Butrans generic

NORTH WALES, Pa. — Teva recently introduced its authorized generic of Butrans (buprenorphine) transdermal system. The transdermal patch is a partial opioid agonist indicated to manage pain that requires around-the-clock long-term opioid treatment for which alternative treatment options are inadequate. 

Teva’s authorized generic is available in 5-, 10-, 15- and 20-mcg/hour strengths.

The product carries a boxed warning for addiction, abuse and misuse; life-threatening respiratory depression; accidental exposure; neonatal opioid withdrawal syndrome; and risks from concomitant use with benzodiazepines or other central nervous system depressants.